January 20, 2014
The Ministry of Health, Labor and Welfare (MHLW) approved 28 new drug products, including Japan’s first selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor Suglat 25 mg/50 mg Tablets (ipragliflozin L-proline), on January 17. Among the 28 products are Nippon Boehringer Ingelheim’s lung...read more